Journal of pediatric Surgery Article review: September 2022 part 1

The traditional teaching held that venous tumor thrombus in Wilms tumor mandated radical nephroureterectomy on the affected side 2:15. When bilateral disease presents with thrombus, that paradigm collapses—bilateral nephrectomy is not an option 4:21. This discussion traces how aggressive neoadjuvant chemotherapy and staged surgical planning make nephron preservation feasible even in this most challenging scenario.

The chemotherapy foundation enables the surgical options. Twelve weeks of three-drug neoadjuvant therapy—vincristine, actinomycin D, and doxorubicin—precedes any operative intervention 2:53. This duration and combination are not arbitrary; they represent the threshold that allows tumor and thrombus downsizing sufficient to attempt nephron-sparing resection in selected cases 3:50. Without this specific regimen, the surgical discussion that follows would not be possible.

Staging the procedures distributes the physiologic burden and preserves decision flexibility. Two sequencing strategies emerged from this series 3:11. The first approach addresses the simpler side initially, allows recovery, then returns to tackle the thrombus-bearing kidney—at that point you know whether nephron-sparing remains feasible or whether the complexity demands radical resection. The alternative inverts the sequence: perform radical nephrectomy with thrombectomy first, then return for nephron-sparing on the remaining kidney once you have secured one definitive clearance. The choice between these depends on tumor response to chemotherapy and the surgeon's assessment of which kidney offers better salvage potential. Neither approach is universally superior; the value lies in recognizing that staging itself—rather than attempting bilateral resection in one operation—is the enabling principle.

Nephron-sparing with thrombus removal achieves durable renal function without transplant. In this series of five patients, four underwent nephron-sparing surgery of all tumors; one required unilateral radical nephroureterectomy with contralateral nephron-sparing 3:00. Three patients developed stage 2 or 3 chronic kidney disease managed medically 3:50. Critically, no patient required renal replacement therapy or transplant to date 3:50. The outcome benchmark here is not normal renal function—it is independence from dialysis and transplant in children who would otherwise face bilateral nephrectomy. Stage 2 or 3 CKD in this context represents success, not complication.

ICG fluorescence guidance showed feasibility but not yet clinical advantage. A separate investigation examined indocyanine green administered 24 hours preoperatively to enhance intraoperative tumor visualization 6:06 6:17. The timing matters—24-hour uptake optimizes fluorescence 6:17. The unexpected finding was an inverse pattern: healthy renal parenchyma fluoresced while tumor tissue did not 6:37. Every nephron-sparing procedure succeeded, but surgical margins matched those achieved without ICG 6:44 6:44. This represents proof of concept without demonstrated benefit 7:08 7:08. The discussants emphasized that future applications will require targeting specific cellular receptors rather than relying on passive dye uptake 7:28.

The clinical question this work answers is whether nephron preservation remains possible when bilateral disease and intravascular thrombus coexist. The answer is yes, in selected cases, using protocolized neoadjuvant chemotherapy and staged surgical planning 3:50 4:31. The rarity of this presentation—bilateral Wilms with intravascular thrombus—means few surgeons will accumulate personal experience 4:13. The value of this series lies in establishing that the traditional reflex toward radical resection can be overcome when bilateral disease forces the issue. The patients who benefit are those who would otherwise face certain dialysis dependence; for them, stage 2 or 3 CKD managed medically is a meaningful preservation of quality of life.

The traditional teaching held that venous tumor thrombus in Wilms tumor mandated radical nephroureterectomy on the affected side 2:15. That assumption becomes untenable when both kidneys harbor tumor—bilateral nephrectomy is not an option 4:21. This discussion traces how neoadjuvant chemotherapy and staged surgical planning make nephron preservation possible even in these complex cases.

The chemotherapy foundation matters more than you think. All five patients in this series received twelve weeks of three-drug neoadjuvant chemotherapy: vincristine, actinomycin D, and doxorubicin 2:53. This is not simply tumor debulking—it is what makes the surgical decision tree viable. Without adequate response to this regimen, the staged approach described below collapses. The discussants emphasized that this protocol enabled nephron-sparing surgery even with intravascular thrombus present 3:50.

Staging the procedures buys you information and recovery time. When facing bilateral disease with thrombus, you have two sequencing options 3:11. First approach: operate on the easier side, allow the patient to recover, then reassess whether nephron-sparing is feasible on the thrombus side. Second approach: if you anticipate needing radical nephrectomy, perform that with thrombectomy first, then return for nephron-sparing on the remaining kidney 3:11. The choice depends on your read of tumor biology after chemotherapy, but both strategies recognize that attempting everything in one operation may compromise what you can preserve.

Nephron-sparing with thrombus removal is technically achievable. Four of five patients underwent nephron-sparing surgery on all tumors; one required unilateral nephroureterectomy with contralateral nephron-sparing 3:00. The study demonstrates that unilateral or bilateral nephron-sparing with thrombus removal can achieve good outcomes 4:31. This is the operational finding—what was once considered obligatory radical surgery can be converted to preservation in selected cases.

The renal function outcomes justify the approach. Three patients developed stage 2 or 3 chronic kidney disease managed medically 3:50. No patient required renal replacement therapy or transplantation 3:50. This is the outcome that matters: preserved native kidney function without dialysis dependence. The discussants noted these cases are rare 4:13, but when they occur, this approach offers a path that avoids the morbidity of bilateral nephrectomy.

ICG fluorescence guidance shows promise but not yet clinical advantage. A separate study examined indocyanine green administered 24 hours before surgery to maximize tumor visualization 6:06 6:17. The finding was unexpected: healthy kidney tissue fluoresced while tumor did not—an inverse pattern 6:37. Every nephron-sparing procedure succeeded, but surgical margins were unchanged compared to surgery without ICG 6:44 6:44. One discussant characterized this as proof of concept that worked but didn't yet offer benefit 7:08. The technology is feasible for renal tumor surgery but has not demonstrated superiority over standard technique 7:08.

The future of fluorescence guidance lies in molecular targeting. The discussants agreed that indocyanine green and similar compounds represent the direction of surgical oncology for both mass resection and anatomic identification 5:37. The next evolution will involve specific targeting at the cellular level—conjugating fluorophores to antibodies or ligands that bind tumor-specific surface receptors 7:28. The current work establishes that real-time fluorescent visualization is operationally feasible 5:23; what remains is making it discriminate better than the surgeon's eye and tactile sense.

The central teaching is this: bilateral Wilms tumor with intravascular thrombus is no longer an automatic indication for radical surgery on the thrombus side. Twelve weeks of three-drug chemotherapy, staged procedures that allow reassessment, and meticulous technique make nephron preservation possible. The patients in this series retained native kidney function without dialysis. That outcome—not the technical feat of the operation—is what changes practice.